Clearsight Advisors, Inc. (“Clearsight”) is pleased to announce the completion of another highly successful transaction. Clearsight served as the exclusive strategic and financial advisor to PharmaCM, a business unit of Deloitte in its acquisition by TrialScope, a life sciences technology company.
PharmaCM is an innovative technology company and global leader in compliance and content management solutions for the Life Sciences Industry. PharmaCM’s flagship product, PharmaCM Clinical Trial (CT) is a clinical trial disclosure solution that enables pharmaceutical and biotech companies to manage the complexity of complying with the regulatory requirements imposed by ClinicalTrials.gov and other international clinical trial registries. CT is currently implemented by 7 of the top 15 global pharmaceutical companies.
Across virtually every industry sector, finance, healthcare, energy, pharmaceutical, CPG, etc. companies are facing unprecedented compliance challenges and regulatory scrutiny. As a result, it is becoming increasingly more difficult and costly to manage and comply with the complexity of the various requirements imposed by regulators. Further exacerbating this issue is the continued reliance on archaic systems and outdated and often manual processes still employed at firms large and small. With this backdrop, there are a number of new and exciting technology solutions emerging that tackle the unique content management and workflow challenges required to ensure compliance with industry regulations.
“PharmaCM is at the forefront of the movement in the Life Sciences Sector towards sponsors use of third-party technology to manage regulatory compliance. PharmaCM’s leadership team saw the increasing role compliance was going to play in the clinical trial process as early as 2007. In response, they built what many consider to be the leading SaaS platform for clinical trial compliance in the market today. We believe the combination with TrialScope will allow PharmaCM to reach the next level and transform the industry’s antiquated approach to compliance,” said John Rakowski, Director of Clearsight Advisors.
This transaction represents Clearsight’s third Life Sciences deal in the past 12 months. As the Life Sciences sector strives to reinvent itself, we are seeing a burgeoning demand for software and professional services. Not surprisingly, corporate and financial investors alike are taking notice, which has led to a highly favorable deal environment for companies serving the Pharmaceutical & Life Sciences market.